Your Health, We Care
Release date: 2024-11-19 17:12:07 Recommended: 76
Vitrakvi, a highly selective oral tropomyosin receptor kinase (TRK) inhibitor, larotrectinib, has demonstrated significant activity in adult and pediatric TRK-fusion cancers. What is the effect of neoadjuvant larotrectinib, i.e., children with locally advanced TRK fusion sarcoma are treated with Vitrakvi larotrectinib before surgery and subsequently undergo surgical resection.
A total of five children with TRK fusion sarcoma were included in the study, who received neoadjuvant treatment with Vitrakvi larotrectinib and underwent surgical resection.
The five patients (median age 2 years; range: 0.4-12 years), with locally advanced infantile fibrosarcoma (3) or soft tissue sarcoma (2). Four patients had disease refractory to standard therapy. According to version RECIST1.1, all five patients achieved a partial response to Vitrakvi larotrectinib and underwent surgical resection after a median of 6 cycles (range 4-9 cycles). Surgical resection was R0 (negative margin, no tumor at the edge of ink resection) in 3 cases, R1 (macroscopic residual tumor at the resected margin) in 1 case, and R2 (macroscopic residual tumor at the resected margin) in 1 case. 3 patients achieved complete (2 patients) or near-complete (>98% treatment response; 1 patient) pathological reaction.
These patients are still in follow-up and will no longer receive Vitrakvi larotrectinib for at least 7 to 15 months after surgery. Two patients had tumors alive and positive resection margins at the time of surgical resection, and continued adjuvant larotrectinib. None of the patients experienced postoperative complications or wound healing problems.
Children with locally advanced TRK fusion sarcoma can be surgically resected after treatment with the selective TRK inhibitor larotrectinib. Vitrakvi larotrectinib is necessary as a preoperative treatment for children with newly diagnosed TRK fusion sarcoma.
Before purchasing, patients should learn more about the indications, dosage, adverse reactions and other key information of the generic larotrectinib drug.
Regardless of the channel through which the drug is purchased, patients should verify the source and quality of the drug. There is an option to purchase generic drugs from well-known pharmaceutical companies to ensure the quality and efficacy of the drug.
Patients should consult their physician before purchasing and using generic larotrectinib. Doctors can provide personalized medication guidance and recommendations according to the patient's specific condition and medication needs.
Patients should strictly follow the doctor's guidance when using generic larotrectinib. In case of adverse reactions or aggravation of the condition, you should seek medical attention in time and inform the doctor of the drug you are using.
